Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab

 Roche on Thursday reported a 3 percent increase in pharmaceutical division revenues and strong performance from several precision oncology products, such as Phesgo (pertuzumab/trastuzumab/hyaluronidase) and Tecentriq (atezolizumab).